Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 216Stomach Neoplasms 166Rectal Neoplasms 146Pancreatic Neoplasms 81Colonic Neoplasms 77Neoplasm Metastasis 67Esophageal Neoplasms 55Neoplasms 31Adenocarcinoma Of Esophagus 29Cholangiocarcinoma 28Carcinoma, Hepatocellular 26Adenocarcinoma 26Biliary Tract Neoplasms 23Lymphoma, Large B-Cell, Diffuse 19Recurrence 17Carcinoma, Non-Small-Cell Lung 16Gallbladder Neoplasms 14Breast Neoplasms 14Head and Neck Neoplasms 11Locally Advanced Rectal Cancer 10Liver Neoplasms 10Gastrointestinal Neoplasms 10Esophageal Squamous Cell Carcinoma 9Peritoneal Neoplasms 8Ovarian Neoplasms 8Colorectal Cancer Metastatic 7Bile Duct Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Extranodal NK-T-Cell 5

Interventions

zolbetuximab 1trifluridine tipiracil drug combination 1tipiracil 1camrelizumab 1Trifluridine 1Taxes 1Oxaliplatin 1HMPL-013 1Docetaxel 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastric Cancer Adenocarcinoma Metastatic × Oxaliplatin × Clear all
NCT00517829 2016-11-28

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

US Oncology Research

Phase 2 Completed
150 enrolled 12 charts
Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡